The effect of mogamulizumab on the aberrant T cell population in the peripheral blood - A monocentric retrospective analysis.
Mogamulizumab
Mycosis fungoides
Sézary syndrome
Journal
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
ISSN: 1610-0387
Titre abrégé: J Dtsch Dermatol Ges
Pays: Germany
ID NLM: 101164708
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
24
12
2022
accepted:
07
05
2023
medline:
14
9
2023
pubmed:
4
7
2023
entrez:
4
7
2023
Statut:
ppublish
Résumé
The effect of mogamulizumab in cutaneous T-cell lymphoma (CTCL) on T cells (TC) in the peripheral blood and its potential role to navigate treatment intervals are explored. We investigated within a retrospective monocentric analysis the effect of mogamulizumab on the CD3 Thirteen patients with CTCL were included. After four cycles there was a mean reduction of 57% in CD3 Already after one dose of mogamulizumab, aberrant TCP and, to a lesser extent, normal TC decrease. We did not observe a clear correlation between TCP and the efficacy of mogamulizumab, but further studies with larger numbers of patients are needed.
Sections du résumé
BACKGROUND AND OBJECTIVES
The effect of mogamulizumab in cutaneous T-cell lymphoma (CTCL) on T cells (TC) in the peripheral blood and its potential role to navigate treatment intervals are explored.
METHODS
We investigated within a retrospective monocentric analysis the effect of mogamulizumab on the CD3
RESULTS
Thirteen patients with CTCL were included. After four cycles there was a mean reduction of 57% in CD3
CONCLUSIONS
Already after one dose of mogamulizumab, aberrant TCP and, to a lesser extent, normal TC decrease. We did not observe a clear correlation between TCP and the efficacy of mogamulizumab, but further studies with larger numbers of patients are needed.
Substances chimiques
Dipeptidyl Peptidase 4
EC 3.4.14.5
mogamulizumab
YI437801BE
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
992-1002Informations de copyright
© 2023 Deutsche Dermatologische Gesellschaft (DDG).
Références
European Medicines Agency. Product information Poteligeo. Available from: https://www.ema.europa.eu/en/documents/product-information/poteligeo-epar-product-information_de.pdf [Last accessed December 12, 2022].
Najidh S, Van der Sluijs Gelling AJ, Cozzio A, et al. Immunophenotypic identification and characterization of CTCL tumor cells in blood using standardized flow cytometry: a European multicenter study. European Journal of Cancer, Volume 173S1, Abstractband EORTC CLTG meeting Madrid, September 2022.
Olsen EA, Whittaker S, Willemze R, et al. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood. 2022;140(5):419-437.
Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713-1722.
Beygi S, Duran GE, Fernandez-Pol S, et al. Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma. Blood. 2022;139(26):3732-3736.
Querfeld C. Mechanisms of resistance to mogamulizumab. Blood. 2022;139(26):3674-3676.
Pulitzer MP, Horna P, Almeida J. Sézary syndrome and mycosis fungoides: An overview, including the role of immunophenotyping. Cytometry B Clin Cytom. 2021;100(2):132-138.
Najidh S, Tensen CP, van der Sluijs-Gelling AJ, et al. Improved Sézary cell detection and novel insights into immunophenotypic and molecular heterogeneity in Sézary syndrome. Blood. 2021;138(24):2539-2554.
Yu B, Koga T, Urabe K, et al. Differential regulation of thymus- and activation-regulated chemokine induced by IL-4, IL-13, TNF-alpha and IFN-gamma in human keratinocyte and fibroblast. J Dermatol Sci. 2002;30(1):29-36.
Yang YM, Feng AL, Zhou CJ, et al. Aberrant expression of chemokine receptor CCR4 in human gastric cancer contributes to tumor-induced immunosuppression. Cancer Sci. 2011;102(7):1264-1271.
Cowan RA, Scarisbrick JJ, Zinzani PL, et al. Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial. J Eur Acad Dermatol Venereol. 2021;35(11):2225-2238.
Beylot-Barry M, Booken N, Weishaupt C, et al. Impact of blood involvement on efficacy and time to response with mogamulizumab in mycosis fungoides and Sézary syndrome. J Eur Acad Dermatol Venereol. 2023;37(2):311-316.
Horwitz S, Zinzani PL, Bagot M, et al. Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial. Leuk Lymphoma. 2021;62(13):3109-3118.
Caruso L, Castellino A, Dessì D, et al. Italian real-life experience on the use of mogamulizumab in patients with cutaneous T-cell lymphomas. Cancer Manag Res. 2022;14:3205-3221.
Elsayad K, Rolf D, Sunderkötter C, et al. Low-dose total skin electron beam therapy plus oral bexarotene maintenance therapy for cutaneous T-cell lymphoma. J Dtsch Dermatol Ges. 2022;20(3):279-285.
Assaf C, Dobos G, Zech IM. Care structure of patients with mycosis fungoides and Sézary syndrome in Germany - Care research based on SHI claims data. J Dtsch Dermatol Ges. 2022;20(5):643-651.
Jonak C, Tittes J, Brunner PM, Guenova E. Mycosis fungoides and Sézary syndrome. J Dtsch Dermatol Ges. 2021;19(9):1307-1334.
Lehner GM, Schacht V, Angela Y, et al. Psoriasis vulgaris triggered by treatment with mogamulizumab in a patient with cutaneous T-cell lymphoma. J Dtsch Dermatol Ges. 2021;19(9):1355-1358.